LFB Group

Last updated: 27.11.2018


Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare.


The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.


The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.


LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries.
Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.

Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here